Corvus Pharmaceuticals, Inc. (CRVS): Operating Income
-$42.97M
Year ended 2025-12-31
-$56.96M
Trailing 12 months to 2026-06-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$42.97M | n/m | 2026-03-12, From 2025-01-01 |
| 2024-12-31 | -$27.55M | n/m | 2026-03-12, From 2024-01-01 |
| 2023-12-31 | -$23.41M | n/m | 2026-03-12, From 2023-01-01 |
| 2022-12-31 | -$32.56M | n/m | 2025-03-25, From 2022-01-01 |
| 2021-12-31 | -$38.63M | n/m | 2024-03-19, From 2021-01-01 |
| 2020-12-31 | -$43.76M | n/m | 2023-03-28, From 2020-01-01 |
| 2019-12-31 | -$48.85M | n/m | 2022-03-10, From 2019-01-01 |
| 2018-12-31 | -$49.22M | n/m | 2021-03-25, From 2018-01-01 |
| 2017-12-31 | -$56.52M | n/m | 2020-03-09, From 2017-01-01 |
| 2016-12-31 | -$36.98M | n/m | 2019-03-07, From 2016-01-01 |
| 2015-12-31 | -$13.77M | n/a | 2018-03-01, From 2015-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Corvus Pharmaceuticals, Inc. (CRVS) | 2025-12-31 | -$42.97M | n/m |
| Aldeyra Therapeutics, Inc. (ALDX) | 2025-12-31 | -$35.27M | n/m |
| Werewolf Therapeutics, Inc. (HOWL) | 2025-12-31 | -$60.68M | n/m |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $6.31M | n/m |
| Context Therapeutics Inc. (CNTX) | 2025-12-31 | -$39.70M | n/m |
| Inovio Pharmaceuticals, Inc. (INO) | 2025-12-31 | -$86.82M | n/m |
| Grace Therapeutics, Inc. (GRCE) | 2026-03-31 | -$11.08M | n/m |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | -$2.79M | n/m |
| Adagene Inc. (ADAG) | 2025-12-31 | -$21.44M | n/m |
Compare CRVS, ALDX, HOWL, SPRO side by side · Screen every company in Pharmaceutical Preparations ↗